Navigation Links
International Rectal Microbicide Advocates cheers launch of world's third rectal microbicide trial
Date:10/13/2010

crobicides. Tenofovir gel, for example, is a candidate microbicide specifically developed to prevent vaginal transmission of HIV. In a recent study known as CAPRISA 004, tenofovir gel was found to significantly reduce the risk of HIV among at-risk women who were instructed to use the gel before and after vaginal intercourse. In an ongoing, large-scale effectiveness trial called VOICE Vaginal and Oral Interventions to Control the Epidemic researchers from the U.S. National Institutes of Health-funded Microbicide Trials Network (MTN) are testing daily use of tenofovir gel in African women, with results expected in 2013.

This new Phase I rectal microbicide study, known as MTN-007, aims to determine if rectal use of tenofovir gel is safe, and in particular, does not cause cells in the rectum to become more vulnerable to HIV. Investigators will also ask trial participants questions regarding the gel's desirability. MTN-007 will enroll 60 men and women at the University of Pittsburgh, the University of Alabama at Birmingham, and Fenway Health in Boston. Leading the study is Ian McGowan, M.D., Ph.D., of the University of Pittsburgh, who is also co-principal investigator of the MTN and serves as Scientific Vice-Chair of IRMA.

Little is known about tenofovir gel used rectally, but science is advancing our understanding. Laboratory and animal studies involving rectal application of tenofovir gel have suggested it's safe for testing in humans. In fact, MTN researchers have just completed the first Phase I trial with eighteen participants, called RMP-02/MTN-006, in collaboration with the Microbicide Development Program at the University of California, Los Angeles. While results of RMP-02/MTN-006 are not expected until early 2011, researchers have already recommended modifications to the gel's formulation. MTN-007 is evaluating the new formulation, which still contains the same amount of active drug 1% percent tenofovir but has a lower concentration of g
'/>"/>

Contact: Jim Pickett
jpickett@aidschicago.org
773-600-6407
International Rectal Microbicide Advocates
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UCLA receives $12.5M to lead international project to study proteins implicated in heart disease
2. Pharmaceutical sciences experts present cutting-edge research at international meeting
3. John P. Holdren addresses climate change, stressing need for international cooperation
4. International scientific forum on alcohol research
5. Stem Cells and International Stem Cell Symposium present annual stem cells award
6. Professor Rajeshwar Dayal Tyagi of INRS wins major international award
7. SailPoint Signs International Reseller Agreement with BMC Software
8. University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life
9. $22.5 million grant funds international study of membrane proteins
10. SRI International President and CEO Curtis R. Carlson Named to National Advisory Council on Innovation and Entrepreneurship
11. BIO-key® International to Exhibit at Allscripts 2010 Client Experience Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... farming and relieve the pressure on overexploited fish stocks. ... fish escape? Researchers at the University of Gothenburg have ... are urging caution:,-Until further notice transgenic fish should be ... at the Department of Zoology, University of Gothenburg. ...
... A research report featured on the cover of the September ... http://www.fasebj.org ) describes how Australian scientists developed a new gene ... to transport their cargo into our cells. As a result ... cell,s nucleus far more efficiently than in the past, raising ...
... from natural coal deposits in the Gulf of Alaska ... the Exxon Valdez tanker catastrophe. This clearly disproves the ... observed environmental damage. PAH pollutants were blamed for the ... Alaska. Then a dispute erupted over the origins of ...
Cached Biology News:Risks involved with transgenic fish 2Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes 2Bioavailable contaminants come from the Exxon Valdez oil catastrophe 2
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of ... 2013; while production volume reached close to 1.84 million tonnes in the same ... of 75.5% of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide ...
(Date:7/28/2015)... , July 21, 2015 Research ... addition of the "Biomedical Refrigerators and Freezers ... Trends and Forecast 2014 - 2022" report ... biomedical refrigerators and freezers market has been segmented ... centers, blood banks, and others. The others segment ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... the Deerfield Healthcare Innovations Fund, L.P., which will invest ... therapeutic interventions in genetic diseases, cancer, and orphan diseases. ... that can transform how therapeutics are developed and improve ... The fund, one of the largest healthcare-focused venture funds ...
(Date:7/28/2015)... 2015  Kerastem Technologies announce that the Company has ... Center For Biologics Evaluation and Research (CBER) Office of ... trial investigating the safety and feasibility of the Company,s ... pattern baldness (androgenic alopecia). The phase II ... work in Europe and ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... Chromos Molecular,Systems Inc. ("Chromos" or the "Company") announced ... in the Provinces,of British Columbia, Alberta, Manitoba, Ontario ... the Company effective July 22, 2008. As a,result, ... against the,Company., The Company continues to review ...
... a video interview, new CEO,Andrew Witty comments on GSK,s second ... for the business., The new strategic ... business - Deliver more products of value - ... are available now on, http://www.cantos.com . It,s free to view. ...
... JOLLA, Calif., July 23 Duska Therapeutics,Inc. (OTC ... has,submitted for comment a synopsis of a proposed ... to the U.S. Food and Drug Administration,s (the,"FDA") ... on recent communications with the FDA, including a ...
Cached Biology Technology:Chromos Announces Full Revocation of Cease Trade Orders 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4